Gilead Sciences, Inc. Gets Some Competition (but Not Really) | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 21 December, 2014 by The TZ Newswire Staff

Gilead Sciences, Inc. Gets Some Competition (but Not Really)

AbbVie gains FDA approval for Viekia Pak; but without a discount, it’s hard to see it competing with Harvoni.

See also
- Next Article Euro shaky in subdued market, dollar holds strong
- Previous Article Two More Cops Shot After Yesterday’s Brutal New York "Execution"
Editorial Calender

December 2014

M T W T F S S

1 2 3 4 5 6 7

8 9 10 11 12 13 14

15 16 17 18 19 20 21

22 23 24 25 26 27 28

29 30 31

« Nov Jan »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar